Floatz logo

ik-175

Locally Advanced Solid Tumor

Ikena OncologyPhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

54 Active assets in the Locally Advanced Solid Tumor cohort.

Asset / SponsorPhaseRating
vc004
Jiangsu vcare pharmaceutical technology co., LTD
Phase 3B
Nivolumab
Mohammed Milhem
Phase 2B
Eloxatin
Parabilis Medicines, Inc.
Phase 2B
TRASTUZUMAB
Aiping Zhou
Phase 2B
S-1
Aiping Zhou
Phase 2CCC

View all 50 →

Same molecule, other indications

ik-175 is also rated in:

Bladder Urothelial CarcinomaDormant
CC
Indicative ·
47 / 100
View asset →
urinary bladder disorderDormant
CC
Indicative ·
47 / 100
View asset →
urinary bladder cancerDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →